A first-in-its-class cholesterol-lowering drug is plowing through clinical trials and appears to lower LDL levels significantly more than Merck & Co’s Zetia. ETC-1002 is an oral pill made by Esperion Therapeutics. It is the first in a new class of cholesterol-lowering drugs known as ACL inhibitors. They work by reducing cholesterol synthesis in the liver and increasing LDL receptors that remove cholesterol from the blood. ETC-1002 was pitted against Zetia in a 12-week study involving 348 patients with high LDL, considered the “bad” cholesterol. ETC-1002 reduced LDL an average of 30 percent in patients who received a 180-milligram dose and ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.